Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-8

  Bretin, Florian ^a   Warnock, Geoffrey ^a   Bahri, Mohamed Ali ^a   Aerts, Joël ^a   Mestdagh, Nathalie ^b   Buchanan, Tim ^b   Valade, Anne ^b   Mievis, Frédéric ^a   Giacomelli, Fabrice ^a   Lemaire, Christian ^a   Luxen, André ^a   Salmon, Eric ^a   Seret, Alain ^a   Plenevaux, Alain ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UCB PHARMA   (Belgium)

Author keywords

Dosimetry; Organ harvesting; Preclinical microPET; SV2

Indexed keywords

ETIRACETAM; ETIRACETAM F 18; NERVE PROTEIN; SYNAPTIC VESICLE PROTEIN 2A; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLADDER; BRAIN; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; HUMAN; HUMAN TISSUE; LIVER; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; TISSUE DISTRIBUTION; URINARY EXCRETION;

EID: 84878800043     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-35     Document Type: Article

References (23)

1. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004, 101:9861.
2. Warnock G, Aerts J, Bahri M, Bretin F, Buchanan T, Klitgaard H: Characterization of a novel radiotracer targeting synaptic vesicle protein 2A (SV2A). World Mol Imag Conf 2012:134.
3. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR: MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J NuclMed 1999, 40:37S-61S.
4. Bahri MA, Warnock G, Plenevaux A, Choquet P, Constantinesco A, Salmon E, Luxen A, Seret A: Performance evaluation of the General Electric eXplore CT 120 micro-CT using the vmCT phantom. Nucl Instrum Methods Phys Res, Sect. A 2011, 648:S181-S185.
5. Feldkamp L, Davis L, Kress J: Practical cone-beam algorithm. JOSA A 1984, 1:612-619.
6. Laforest R, Longford D, Siegel S, Newport DF, Yap J: Performance evaluation of the microPET®-FOCUS-F120. IEEE Trans Nucl Sci 2007, 54:42-49.
7. Defrise M, Kinahan P, Townsend DW, Michel C, Sibomana M, Newport D: Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imag 1997, 16:145-158.
8. Bahri MA, Plenevaux A, Warnock G, Luxen A, Seret A: NEMA NU4-2008 image quality performance report for the microPET Focus 120 and for various transmission and reconstruction methods. J Nucl Med 2009, 50:1730-1738.
9. Kirshner A, Ice R, Beierwaltes W: Radiation dosimetry of 19-iodocholesterol [I31I]: the pitfalls of using tissue concentration data (reply). J Nucl Med 1975, 16:248-249.
10. Stabin MG, Sparks RB, Crowe E: OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46:1023-1027.
11. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG: Dose to the fetus from radionuclides in the bladder. Health Phys 1973, 25:147.
12. Stabin MG: Fundamentals of Nuclear Medicine Dosimetry. New York: Springer; 2008.
13. Valentin J: Icrp: The 2007 Recommendations of the International Commission on Radiological Protection. Elsevier Health Sciences; 2008.
14. Protection ICoR: 1990: Recommendations of the International Commission Radiological Protection, Adopted by the Commission in November 1990; 1991:60.
15. Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DHS: Radiation dose estimates for [18 F] 5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol 2008, 10:341-348.
16. Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA: 18F-fluorothymidine radiation dosimetry in human PET imaging studies. J NuclMed 2003, 44:1482-1488.
17. Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM, Krohn KA: [18F] fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001, 42:679-684.
18. Rousset OG, Ma Y, Evans AC: Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998, 39:904-911.
19. Yang Y, Rendig S, Siegel S, Newport DF, Cherry SR: Cardiac PET imaging in mice with simultaneous cardiac and respiratory gating. Phys Med Biol 2005, 50:2979.
20. Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, Itoh M, Miyake M, Watanuki S: Estimation of absorbed dose for 2-[F-18] fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 1998, 25:565-574.
21. Verbruggen A, Coenen HH, Deverre JR, Guilloteau D, Langstrom B, Salvadori PA, Halldin C: Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 2008, 35:2144-2151.
22. Code of Federal Regulations-Drugs for human use, Title 21, Volume 5: http:// www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=361.1.
23. Carson RE, Herscovitch P, Daube-Witherspoon ME: Quantitative Functional Brain Imaging with Positron Emission Tomography. Amsterdam: Elsevier Science; 1998.